Difference between revisions of "Category:BTK inhibitors"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | A class of drugs that inhibit Bruton's tyrosine kinase (BTK). The first drug approved in this class is [[Ibrutinib (Imbruvica)]]. | + | A class of drugs that inhibit Bruton's tyrosine kinase (BTK). The first specific drug approved in this class is [[Ibrutinib (Imbruvica)]], although [[Dasatinib (Sprycel)]] has some demonstrated degree of BTK inhibition<ref>[http://www.ncbi.nlm.nih.gov/pubmed/17684099 The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. Epub 2007 Aug 7.]</ref>. |
| + | |||
| + | ==References== | ||
| + | <references/> | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
Revision as of 19:02, 14 November 2014
A class of drugs that inhibit Bruton's tyrosine kinase (BTK). The first specific drug approved in this class is Ibrutinib (Imbruvica), although Dasatinib (Sprycel) has some demonstrated degree of BTK inhibition[1].
References
Pages in category "BTK inhibitors"
The following 8 pages are in this category, out of 8 total.